1. Co-stimulatory and Co-inhibitory Pathways in Autoimmunity
Qianxia Zhang, Dario A.A. Vignali 
Immunity 
Volume 44, Issue 5, Pages (May 2016)
DOI: /j.immuni
Copyright © 2016 Elsevier Inc. Terms and Conditions

2. Figure 1 Co-stimulatory and Co-inhibitory Pathways in SLE
The hierarchical utilization of co-stimulatory and co-inhibitory receptors and their corresponding ligands is compared in SLE. The extent to which a co-stimulatory or co-inhibitory molecule is utilized is indicted by dark shading (dominant utilization: red or blue, respectively) or light shading (partial utilization: pink or cyan, respectively). Molecules that appear to exhibit differential or controversial function (mixed blue and red) in certain diseases or for which there are no data (gray shading) are also noted.
Immunity  , DOI: ( /j.immuni )
Copyright © 2016 Elsevier Inc. Terms and Conditions

3. Figure 2 Co-stimulatory and Co-inhibitory Pathways in RA
The hierarchical utilization of co-stimulatory and co-inhibitory receptors and their corresponding ligands is compared in RA. The extent to which a co-stimulatory or co-inhibitory molecule is utilized is indicted by dark shading (dominant utilization: red or blue, respectively) or light shading (partial utilization: pink or cyan, respectively). Molecules that appear to exhibit differential or controversial function (mixed blue and red) in certain diseases or for which there are no data (gray shading) are also noted.
Immunity  , DOI: ( /j.immuni )
Copyright © 2016 Elsevier Inc. Terms and Conditions

4. Figure 3 Co-stimulatory and Co-inhibitory Pathways in MS
The hierarchical utilization of co-stimulatory and co-inhibitory receptors and their corresponding ligands is compared in MS. The extent to which a co-stimulatory or co-inhibitory molecule is utilized is indicted by dark shading (dominant utilization: red or blue, respectively) or light shading (partial utilization: pink or cyan, respectively). Molecules that appear to exhibit differential or controversial function (mixed blue and red) in certain diseases or for which there are no data (gray shading) are also noted.
Immunity  , DOI: ( /j.immuni )
Copyright © 2016 Elsevier Inc. Terms and Conditions

5. Figure 4 Co-stimulatory and Co-inhibitory Pathways in T1D
The hierarchical utilization of co-stimulatory and co-inhibitory receptors and their corresponding ligands is compared in T1D. The extent to which a co-stimulatory or co-inhibitory molecule is utilized is indicted by dark shading (dominant utilization: red or blue, respectively) or light shading (partial utilization: pink or cyan, respectively). Molecules that appear to exhibit differential or controversial function (mixed blue and red) in certain diseases or for which there are no data (gray shading) are also noted.
Immunity  , DOI: ( /j.immuni )
Copyright © 2016 Elsevier Inc. Terms and Conditions